2-Ketoisovalerate is used as a therapeutic agent, and a 2-ketoisovalerate-producing organism may serve as a platform for products deriving from this 2-keto acid. We engineered the wild type of Corynebacterium glutamicum for the growth-decoupled production of 2-ketoisovalerate from glucose by deletion of the aceE gene encoding the E1p subunit of the pyruvate dehydrogenase complex, deletion of the transaminase B gene ilvE, and additional overexpression of the ilvBNCD genes, encoding the L-valine biosynthetic enzymes acetohydroxyacid synthase (AHAS), acetohydroxyacid isomeroreductase, and dihydroxyacid dehydratase. 2-Ketoisovalerate production was further improved by deletion of the pyruvate:quinone oxidoreductase gene pqo. In fed-batch fermentations at high cell densities, the newly constructed strains produced up to 188 ؎ 28 mM (21.8 ؎ 3.2 g liter ؊1 ) 2-ketoisovalerate and showed a product yield of about 0.47 ؎ 0.05 mol per mol (0.3 ؎ 0.03 g per g) of glucose and a volumetric productivity of about 4.6 ؎ 0.6 mM (0.53 ؎ 0.07 g liter ؊1 ) 2-ketoisovalerate per h in the overall production phase. In studying the influence of the three branched-chain 2-keto acids 2-ketoisovalerate, 2-ketoisocaproate, and 2-keto-3-methylvalerate on the AHAS activity, we observed a competitive inhibition of the AHAS enzyme by 2-ketoisovalerate.
Corynebacterium glutamicum is a Gram-positive, facultative anaerobic organism that grows on a variety of sugars, alcohols, and organic acids (8, 13, 30, 35, 51) . The organism is mainly used for the industrial production of amino acids, such as L-glutamate, L-lysine, or L-valine (28, 52) . Recent studies also showed the successful use of C. glutamicum for the production of organic acids (D-lactate, succinate), ethanol (24, 36, 37) , xylitol (44) , pantothenate (23) , cadaverin (33, 54) , putrescine (45) , and polyhydroxybutyrate (25) . However, the targeted production of 2-ketoisovalerate with C. glutamicum has thus far not been reported. 2-Ketoisovalerate is the precursor of L-valine, L-leucine, and pantothenate synthesis and serves today as a substitute for L-valine or L-leucine in chronic kidney disease patients (1, 9, 19, 55) . To our knowledge, the 2-ketoisovalerate demand today is exclusively covered by chemical synthesis, which can be done by a variety of methods (10) .
In microorganisms and in plants, 2-ketoisovalerate is synthesized from two molecules of pyruvate in a pathway comprising three reactions, catalyzed by acetohydroxyacid synthase (AHAS; ilvBN gene product), acetohydroxyacid isomeroreductase (AHAIR; ilvC gene product), and dihydroxyacid dehydratase (DHAD; ilvD gene product) (38) (Fig. 1) . In C. glutamicum and many other organisms, these enzymes are also responsible for the biosynthesis of 2-keto-3-methylvalerate (precursor of L-isoleucine) from pyruvate and 2-ketobutyrate ( Fig. 1 ). 2-Ketoisovalerate is converted by transaminase B (ilvE gene product) to L-valine or is further metabolized to either L-leucine or D-pantothenate ( Fig. 1) .
AHAS is the key enzyme of the pathways for the synthesis of the branched-chain amino acids (BCAAs) L-valine, Lisoleucine, and L-leucine and thus is also the key enzyme for the synthesis of the respective branched-chain 2-keto acids. It catalyzes the formation of either 2-acetolactate or 2-aceto-2-hydroxybutyrate (Fig. 1) . The C. glutamicum AHAS consists of two catalytic and two regulatory subunits, which are encoded by ilvB and ilvN, respectively. Together with the AHAIR gene ilvC, they form the ilvBNC operon (11) . On the one hand, AHAS is subject to feedback inhibition by the three BCAAs (14) . On the other hand, expression of the ilvBNC operon is controlled by an attenuation mechanism, leading to an ϳ2-fold-higher expression in response to shortage of BCAAs (34) . Furthermore, it has been shown that 2-ketobutyrate in the medium increases expression of the ilvBNC operon ϳ10-fold by a thus-far-unknown regulatory mechanism (14, 34) . C. glutamicum possesses only a single AHAS, whereas Escherichia coli possesses three AHAS isoenzymes (I, II, and III), differing in their regulation and biochemical properties (56) .
Recently, we identified and functionally characterized the E1p subunit of the pyruvate dehydrogenase complex (PDHC) in C. glutamicum and showed that the activity of this complex is essential for growth of this organism on glucose, pyruvate, or lactate (47) . A PDHC-deficient C. glutamicum strain required either acetate or ethanol as additional carbon source for growth (4, 47) . Further characterization of the PDHC-deficient strain C. glutamicum ⌬aceE showed that the mutant forms significant amounts of L-valine, L-alanine, and pyruvate from glucose when acetate was exhausted from the medium and the growth stopped (7). Plasmid-bound overexpression of the L-valine biosynthesis genes ilvBNCE shifted the product spectrum toward L-valine (7) , and inactivation of the pyruvate:quinone oxidoreductase (pqo gene product) and of the phosphoglucose isomerase (pgi gene product) in C. glutamicum ⌬aceE (pJC4ilvBNCE) resulted in even more efficient L-valine production, i.e., up to 410 mM, with a maximum yield of 0.86 mol per mol of glucose in the production phase (6) .
The successful construction of an L-valine producer from C. glutamicum ⌬aceE prompted us to use the PDHC-deficient strain also as a platform for 2-ketoisovalerate production. In the present study, we rationally engineered C. glutamicum ⌬aceE for the efficient production of this 2-keto acid and analyzed the impact of the three branched-chain 2-keto acids 2-ketoisovalerate, 2-keto-3-methylvalerate, and 2-ketoisocaproate on the activity of the AHAS from C. glutamicum.
MATERIALS AND METHODS
Bacterial strains, plasmids, and oligonucleotides. All bacterial strains, plasmids, and oligonucleotides and their relevant characteristics and sources are given in Table 1 .
DNA preparation and transformation. The isolation of plasmids from E. coli was performed as described previously (16) . Plasmid transfer into C. glutamicum was carried out by electroporation, and the recombinant strains were selected on Luria-Bertani brain heart infusion (LB-BHIS) agar plates containing 0.5% (wt/ vol) potassium acetate and kanamycin (50 g ml Ϫ1 ) (56a). The isolation of chromosomal DNA from C. glutamicum was performed as described previously FIG. 1. 2-Ketoisovalerate, L-valine, and L-isoleucine synthesis from two molecules of pyruvate or from pyruvate plus 2-ketobutyrate, respectively, in C. glutamicum. Abbreviations: AHAS, acetohydroxyacid synthase; AHAIR, acetohydroxyacid isomeroreductase; DHAD, dihydoxyacid dehydratase; TA, transaminase B. (12) . Culture conditions. E. coli was grown aerobically on 2ϫTY complex medium (43) at 37°C as 50-ml cultures in 500-ml baffled Erlenmeyer flasks on a rotary shaker at 120 rpm. Precultures of C. glutamicum were grown in 2ϫTY medium at 30°C. Precultures of C. glutamicum strains with deleted aceE gene were cultivated in the presence of 0.5% (wt/vol) potassium acetate. For 2-keto acid fermentations in shake flasks, the cells of an overnight preculture were washed with 0.9% (wt/vol) NaCl and inoculated into CGXII minimal medium (15) containing 10 g of ammonium sulfate instead of 5 g/liter, 4% (wt/vol) glucose, 1% (wt/vol) potassium acetate, and L-valine, L-leucine, and L-isoleucine (1 mM each), to give an initial optical density at 600 nm (OD 600 ) of ϳ1, corresponding to a biomass concentration of 0.3 g (dry weight)/liter (5). The plasmid-carrying strains were cultivated in the presence of kanamycin (50 g ml Ϫ1 ). C. glutamicum was grown aerobically at 30°C as 50-ml cultures in 500-ml baffled Erlenmeyer flasks on a rotary shaker at 120 rpm or as 300-ml cultures in a glass bioreactor as described before (49) .
The fed-batch fermentations were performed in a 1-liter glass bioreactor (Biostat B; Braun, Melsungen, Germany). The pH was maintained at 7.0 by online measurement by using a standard pH electrode (Mettler Toledo, Giessen, Germany) and the addition of 4 M KOH and 4 M H 2 SO 4 . Foam development was prohibited by manual injection of 20 l of 1:5-diluted Struktol 674 antifoam (Schill & Seilacher, Hamburg, Germany). The dissolved oxygen was measured online by use of a polarimetric oxygen electrode (Mettler Toledo) and was adjusted to 30% of saturation in a cascade by stirring at 100 to 1,200 rpm and aerating with 1 to 2 liters of air per min. During the fed-batch processes, adequate amounts of 50% (wt/vol) glucose and 50% (wt/vol) potassium acetate were injected. All fed-batch fermentations were performed in CGXII medium containing 20 g of ammonium sulfate instead of 5 g/liter and 0.1% (wt/vol) yeast extract.
Chromosomal deletion of ilvE. The chromosomal deletion of ilvE in C. glutamicum ⌬aceE and in C. glutamicum ⌬aceE ⌬pqo was performed by using the suicide vector pK19mobsacB ⌬ilvE. After electroporation and selection on LB-BHIS agar plates containing 0.5% (wt/vol) potassium acetate and kanamycin (50 g ml Ϫ1 ), the screening for mutants was done on 2ϫTY agar plates containing 10% (wt/vol) sucrose and 0.5% (wt/vol) potassium acetate. The replacement at the chromosomal locus was verified by PCR using the primer pair ilvE1-ilvE2.
Analytics. For quantification of substrate consumption and product formation, 1 ml-samples were taken from the cultures and centrifuged at 15,000 ϫ g (10 min at room temperature), and the supernatant was used for determination of amino acids, 2-keto acids, acetate, and glucose concentrations in the culture fluid. The amino acid concentrations were determined by reversed-phase high-pressure liquid chromatography (RP-HPLC) as described before (6) . Glucose and acetate concentrations were determined by enzymatic tests from Roche Diagnostics (Penzberg, Germany). The 2-keto acid concentrations were determined by RP-HPLC with fluorimetric detection (excitation at 361 nm and emission at 448 nm) after precolumn derivatization with 1,2-diamino-4,5-dimethoxybenzene (22) . Separation was carried out at 40°C on a Multohyp octyldecyl silane column (particle size, 5 m; 125 by 4 mm; CS-Chromatographie, Langerwehe, Germany). The elution buffer consisted of a polar phase (water) and a nonpolar phase (methanol). Quantification was done by calculation of the concentration using an internal standard (100 M 2-ketovalerate) and by a five-point calibration curve for 2-ketoisovalerate and pyruvate.
Determination of AHAS activities and kinetic parameters. The standard assay for determination of AHAS activities was carried out using the colorimetric single point method (29) . C. glutamicum cells were cultivated in minimal medium containing 2% (wt/vol) glucose to an OD 600 of ϳ5 and harvested by centrifugation (4,200 ϫ g, 10 min at 4°C). The cells were washed three times with ice-cold 2% (wt/vol) KCl at 4°C, resuspended in disruption buffer (100 mM potassium phosphate buffer [pH 7.3], containing 0.5 mM dithiothreitol and 20% [vol/vol] glycerol), and disrupted with a RyboLyser at 4°C. After centrifugation at 20,800 ϫ g and 4°C for 30 min, the supernatant was used for the assays. The protein concentration was quantified with the BCA protein assay (Pierce) with bovine serum albumin as standard.
The reaction mixture (5 ml) for determination of the specific AHAS activity contained 100 mM potassium phosphate buffer (pH 7.3), 10 mM MgCl 2 , 100 M flavin adenine dinucleotide, and 50 mM pyruvate. The reaction was started by adding 500 l of diluted cell extract and was stopped by adding 100 l of 50% (vol/vol) H 2 SO 4 to 1 ml of the reaction mixture. Linearity over the time was proven by stopping the enzyme assay at four different time points. Then, the assay solution was incubated for 30 min at 37°C to allow the spontaneous conversion of 2-acetolactate to acetoin. The concentration of acetoin was determined by the method of Westerfeld (58) . The assays were linear over time and proportional to the protein concentration.
To test for inhibition of the AHAS activity by 2-keto acids, the sodium salts of 2-ketoisovalerate, 2-ketoisocaproate, and 2-keto-3-methylvalerate (all obtained from Sigma-Aldrich, Steinheim, Germany) were used.
For determination of the Michaelis-Menten constant (K m ) and the maximal reaction velocity (V max ) for pyruvate, 10 pyruvate concentrations ranging from 2.5 to 60 mM were used, and the formation of 2-acetolactate was monitored as described above. For the determination of K m and V max for pyruvate in the presence of 50 mM 2-ketoisovalerate, nine pyruvate concentrations ranging from 5 to 100 mM were used. K m and V max values were calculated using the HanesWilkinson plot. One micromole of 2-acetolactate formed per milligram of protein per minute corresponds to one unit.
RESULTS
C. glutamicum ⌬aceE ⌬ilvE forms pyruvate and 2-ketoisovalerate. Previously, we constructed and analyzed the E1p-deficient mutant, C. glutamicum ⌬aceE, which carries a deletion in the chromosomal aceE locus, shows no PDHC activity, and is unable to grow in minimal medium containing glucose as the sole carbon and energy source, unless supplemented with acetate or ethanol (4, 47) . Based on this mutant, we constructed the C. glutamicum ⌬aceE ⌬ilvE double mutant, which is also devoid of the transaminase B gene ilvE. As expected from previous results obtained with C. glutamicum ⌬ilvE (32), the double-mutant C. glutamicum ⌬aceE ⌬ilvE was auxotrophic for the BCAAs L-leucine and L-isoleucine and bradytrophic for L-valine (data not shown). In contrast to C. glutamicum ⌬ilvE, the C. glutamicum ⌬aceE ⌬ilvE double mutant was auxotrophic for acetate as an additional carbon source (Fig. 2) . In minimal medium with 2% (wt/vol) glucose and L-valine, L-leucine, and L-isoleucine (1 mM each), C. glutamicum ⌬ilvE showed a growth rate of 0.26 h Ϫ1 and reached an OD 600 of 24 after 24 h. In minimal medium containing 1% (wt/vol) glucose and the three BCAAs and also containing 1% (wt/vol) potassium acetate, both, C. glutamicum ⌬ilvE and C. glutamicum ⌬aceE ⌬ilvE grew with the same growth rate of 0.29 h Ϫ1 to OD 600 values of 20 and 16, respectively (Fig. 2 ). This growth behavior was comparable to that of C. glutamicum wild type (WT) ( ϭ 0.32 h Ϫ1 , final OD 600 of 20). To test C. glutamicum ⌬ilvE and C. glutamicum ⌬aceE ⌬ilvE for their abilities to form organic acids, 2-keto acids, and/or amino acids, shake-flask growth experiments were performed in minimal medium with 4% (wt/vol) glucose, 1% (wt/vol) potassium acetate, and L-isoleucine, L-leucine, and L-valine (1 mM each). Growth, substrate (glucose and acetate) utilization, and product accumulation were monitored over the course of the experiment. C. glutamicum ⌬ilvE grew at a growth rate of ϳ0.28 h Ϫ1 (0 h Ϫ12 h), reached a final OD 600 of ϳ42 after 24 h, metabolized glucose and acetate simultaneously, and did not produce any of the tested metabolites in concentrations higher than 1 mM (Fig. 3A) . For the first 12 h, C. glutamicum ⌬aceE ⌬ilvE also grew exponentially at a growth rate of ϳ0.27 h Ϫ1 , consumed glucose and acetate simultaneously, and reached an OD 600 of 19 after 24 h. As observed before for the PDHC-deficient strain C. glutamicum ⌬aceE (7), C. glutamicum ⌬aceE ⌬ilvE stopped growth after consumption of the acetate but continued to metabolize glucose and started to produce significant amounts of pyruvate, L-alanine, and 2-ketoisovalerate (Fig. 3B) . After 72 h of cultivation and complete consumption of the glucose, C. glutamicum ⌬aceE ⌬ilvE accumulated about 76 mM pyruvate, 25 mM L-alanine, 3 mM Lvaline, and 40 mM 2-ketoisovalerate.
2-Ketoisovalerate production by C. glutamicum ⌬aceE ⌬ilvE overexpressing ilvBNCD. The relatively high extracellular pyruvate and L-alanine concentrations in the culture broth of C. glutamicum ⌬aceE ⌬ilvE indicated a limitation of the pathway converting pyruvate to 2-ketoisovalerate, i.e., a limitation of the respective enzyme activities. To overcome such a limitation, we transformed C. glutamicum ⌬aceE ⌬ilvE with plasmid pJC4ilvBNCD, carrying the genes encoding the three enzymes AHAS, AHAIR, and DHAD, which catalyze 2-ketoisovalerate synthesis from pyruvate (see Fig. 1 ). The growth of and product formation by C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) in minimal medium containing glucose and acetate was monitored. As shown in Fig. 3C , C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) grew within 10 h to an OD 600 of ϳ18 with a growth rate of ϳ0.27 h Ϫ1 and consumed acetate completely and glucose to a minor part. After depletion of the acetate, the cells stopped growth, continued to metabolize glucose, and produced ϳ27 mM pyruvate, 8 mM L-alanine, 10 mM L-valine, and ϳ95 mM 2-ketoisovalerate within 72 h, showing that plasmid-bound overexpression of ilvBNCD led to a more efficient conversion of pyruvate to 2-ketoisovalerate.
Fed-batch fermentations with C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) and C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD). In order to test the suitability of C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) for an improved 2-ketoisovalerate production process, we established a fed-batch fermentation based on a mixed substrate. The fermentations were carried out in minimal medium initially containing 4% (wt/vol) glucose, 1% (wt/vol) potassium acetate, 0.1% (wt/vol) yeast extract, and L-isoleucine, L-leucine, and L-valine (2 mM each). To allow growth to higher cell densities, acetate was added twice to the growing cells. By this method, C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) reached an OD 600 of ϳ38 after 14 h (Fig. 4A) . With depletion of the acetate, the cells stopped growing, continued to metabolize glucose, and started to produce 2-ketoisovalerate. C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) excreted ϳ85 mM 2-ketoisovalerate within 44 h (Fig. 4A) with a volumetric productivity of 1.9 mM h Ϫ1 and showed a maximal substrate-specific yield (Y P/S ) of 0.44 mol of 2-ketoisovalerate per mol of glucose between 12 and 26 h. In addition, C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) excreted ca. 2 mM pyruvate, 1 mM L-alanine, and 8 mM Lvaline into the medium after 56 h of fermentation.
Pyruvate:quinone oxidoreductase (PQO; pqo gene product) in C. glutamicum catalyzes the oxidative decarboxylation of pyruvate to acetate and CO 2 with a quinone as the physiological electron acceptor and potentially can compete with the AHAS for pyruvate (46) . To study the relevance of the PQO for 2-ketoisovalerate production, we deleted ilvE in C. glutamicum ⌬aceE ⌬pqo (48) , transformed the resulting strain with plasmid pJC4ilvBNCD and carried out fed-batch fermentations as described above. As shown in Fig. 4B, the   FIG. 3 . Growth (OE) and 2-ketoisovalerate production (Ⅺ) of C. glutamicum ⌬ilvE (A), C. glutamicum ⌬aceE ⌬ilvE (B), and C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) (C) in shake flask experiments in minimal medium with glucose (F), acetate (), and L-isoleucine, Lleucine, and L-valine (1 mM each). By-products: छ, L-alanine; ‚, L-valine; E, pyruvate. The figure shows one representative data set of three independent experiments, all three showing comparable results. (Fig. 4B ) with a volumetric productivity of 5.0 mM h Ϫ1 and showed a maximal Y P/S of 0.56 mol of 2-ketoisovalerate per mol of glucose between 16 and 31 h. Furthermore, the cells excreted about 20 mM L-valine and about 5 mM both L-alanine and pyruvate after 56 h of fermentation. The remaining L-alanine and L-valine formation by both C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) and C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD) might be due to amination of pyruvate and of 2-ketoisovalerate by aminotransferases AlaT and AvtA, respectively (31, 32) . Figure 5 summarizes the averages of 2-ketoisovalerate accumulation, the molar Y P/S values, and the volumetric productivities in the overall production phases of both strains calculated for three independent fermentations. C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) produced about 90 Ϯ 16 mM 2-ketoisovalerate with a Y P/S of about 0.38 Ϯ 0.10 mol per mol of glucose. PQO deficiency resulted in a drastic increase of 2-ketoisovalerate accumulation (188 Ϯ 28 mM) and a Y P/S of 0.47 Ϯ 0.04 mol per mol of glucose. The volumetric productivity increased by the pqo deletion more than 2-fold from 2.0 Ϯ 0.5 to 4.6 Ϯ 0.6 mM 2-ketoisovalerate per h. Taken together, our results demonstrate that C. glutamicum ⌬aceE ⌬pqo ⌬ilvE with plasmid-bound overexpression of the L-valine biosynthetic genes ilvBNCD is a useful basis for the overproduction of 2-ketoisovalerate and/or its derivatives. However, the observation that C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD) still excreted significant amounts of L-alanine and pyruvate into the medium suggests that the pathway from pyruvate to 2-ketoisovalerate still contains a bottleneck(s) for an improved 2-ketoisovalerate production process.
It is evident that 2-ketoisovalerate production with the PDHC-deficient C. glutamicum strains described here occurred only after growth has stopped (see Fig. 3B , 3C, 4A, and 4B). Growth-decoupled production was also observed with PDHC-deficient L-valine producer strains (6, 7); however, the replacement of acetate by ethanol in the medium already in the course of the growth phase resulted in L-valine production (4). To study the effect of acetate replacement by ethanol on 2-ketoisovalerate production, we carried out fed-batch fermentations with C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD) and added 1% (vol/vol) of ethanol instead of 1% (wt/vol) of 
FIG. 5. Comparison of final 2-ketoisovalerate (KIV) concentrations (A)
, substrate-specific product yields (Y P/S in mol KIV per mol of glucose, given for the production phase t ϭ 16 to 56 h) (B), and volumetric productivity (in mM KIV per h, given for the production phase t ϭ 16 to 56 h) (C) in cultures of C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) (Ⅺ) and C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD) (u). Means are from three independent experiments; error bars indicate standard deviations. AHAS inhibition by 2-keto acids. AHAS is the key enzyme of L-valine, L-leucine, and L-isoleucine biosynthesis and thus also that of the respective 2-keto acids (see the introduction and Fig. 1 ). The AHAS from C. glutamicum WT is feedback inhibited to ca. 50% by L-valine, L-leucine, or L-isoleucine; however, there is no cumulative effect for all three BCAAs and AHAS inhibition remains at 50 to 60% inhibition in the presence of all three BCAAs (14, 17, 29) . Due to the structural similarities of the BCAAs with their corresponding 2-keto acids, it was conceivable that the latter also have an effect on AHAS activity. Therefore, we tested the effect of 2-ketoisovalerate, 2-ketoisocaproate, and 2-keto-3-methylvalerate on the specific AHAS activity. As shown in Table 2 , the presence of 100 mM 2-ketoisovalerate (representing concentrations possibly relevant only in producer strains) resulted in an ca. 50% inhibition of the AHAS, whereas the same concentrations of 2-ketoisocaproate and 2-keto-3-methylvalerate affected the enzyme only to a minor extent. On combination of the three 2-ketoacids at 100 mM each, the inhibition did not exceed 65%. Applying 2-ketoisovalerate at concentrations raging from 6.25 to 400 mM, we observed decreasing AHAS activities ranging from 93 to 12% of the activity determined without the effector (data not shown).
We also tested the effect of the three branched chain 2-ketoacids on the ⌬C-T ilvN variant of the C. glutamicum AHAS, which carries a C-terminal deletion of IlvN and which is insensitive to L-valine, L-leucine, and L-isoleucine (5) . As shown in Table 2 , AHAS ⌬C-T ilvN showed the same sensitivity toward the branched-chain 2-keto acids as the WT AHAS, indicating that 2-ketoisovalerate inhibition is mechanistically different from AHAS inhibition by the BCAAs. These results suggest that the regulatory subunit IlvN of the C. glutamicum AHAS, which is responsible for the inhibition by the BCAAs, is not responsible for the inhibition by the respective 2-keto acids.
To further characterize the inhibitory effect of 2-ketoisovalerate on the WT AHAS activity, we determined the kinetic parameters of the enzyme in crude extracts in the presence of 50 mM 2-ketoisovalerate and compared them to the respective values without inhibitor. As shown in Fig. 6 , the V max with or without inhibitor was about the same (77 or 70 mU/mg, respectively), whereas the K m for pyruvate increased in the presence of 2-ketoisovalerate from 7.8 to 24.7 mM.
These results show that AHAS inhibition by 2-ketoisovalerate takes place at the active site of the enzyme, probably at the pyruvate binding site of the catalytic subunit IlvB, and the results show that the C. glutamicum WT AHAS is competitively inhibited by 2-ketoisovalerate.
DISCUSSION
Based on previous experience on tailoring C. glutamicum for high-yield L-valine production (6, 7) and on the observation that L-valine-producing C. glutamicum strains form 2-ketoisovalerate as an undesired by-product (3), we constructed here for the first time a defined C. glutamicum strain efficiently producing 2-ketoisovalerate with high yields and productivities. Since 2-ketoisovalerate is a precursor or an intermediate for the synthesis of a variety of further compounds, it is obvious that an optimized 2-ketoisovalerate production strain also may serve as an ideal platform for interesting products deriving from this 2-keto acid, e.g., L-leucine, pantothenate, or the potential biofuel isobutanol. Atsumi et al. (2) described an efficient Escherichia coli production process in which glucose was converted to isobutanol via 2-ketoisovalerate and very recently, Smith et al. (50) reported also on engineering C. glutamicum for isobutanol production by harnessing the 2-ketoisovalerate pathway. Although C. glutamicum showed a relatively high isobutanol tolerance compared to E. coli, the final titer, the yield, and the productivity were suboptimal, i.e., 66 mM from about 250 mM glucose within 96 h (2, 50) . It is tempting to speculate that the combination of the engineering strategies for 2-ketoisovalerate (the present study) and isobutanol production (50) will result in an optimized isobutanol producer strain of C. glutamicum with higher yield and productivity. Studies in this direction are under way. Our most efficient 2-ketoisovalerate-producing C. glutamicum strain was constructed by stepwise inactivation of the genes ilvE, aceE, and pqo, and plasmid-bound overexpression of ilvBNCD. C. glutamicum ⌬ilvE and C. glutamicum ⌬aceE ⌬ilvE required L-valine, L-leucine, and L-isoleucine for optimal growth in minimal medium, corroborating the previous findings of Marienhagen et al. (32) that the ilvE product (transaminase B) is the main transaminase responsible for the amination reactions in BCAA biosynthesis. The deletion of ilvE and aceE in C. glutamicum WT already resulted in significant 2-ketoisovalerate production. However, the formation of even higher concentrations of pyruvate indicated a limitation of the carbon flux from pyruvate into the 2-ketoisovalerate branch. In fact, overexpression of ilvBNCD and, in particular, the deletion of pqo shifted the carbon flux significantly in the direction of 2-ketoisovalerate, leading to higher final titers of this product and only low concentrations of the by-products pyruvate, Lalanine, and L-valine. The overexpression of ilvBNC or ilvBNCD in C. glutamicum ⌬aceE has previously been shown to be necessary for a more efficient carbon flux from pyruvate toward L-valine (3, 6, 40) . However, even the pJC4-based overexpression of ilvBNCD might not necessarily completely overcome a limitation in this pathway since expression of ilvBNC is partially controlled by an attenuation mechanism involving antitermination (34) . Probably due to this regulation, inactivation of the L-isoleucine biosynthesis in a L-valine producing C. glutamicum strain with pJC4-based ilvBNCD overexpression led to a higher L-valine accumulation (27, 40) . Similarly, Lange et al. (27) observed a positive effect on L-valine formation by induced L-isoleucine limitation in the same strain, and these authors showed that ilvBN mRNA levels and AHAS activity were increased under these conditions. However, since our transaminase B-deficient strains are L-isoleucine auxotrophic and supplemented only with low concentrations of L-isoleucine, it can be speculated that ilvBNCD expression is not a limiting factor in the 2-ketoisovalerate production.
Whereas the deletion of the pqo gene in an L-valine producer of C. glutamicum resulted (only) in ca. 13% higher Lvaline accumulation (6) , pqo deletion in our 2-ketoisovalerate producer led to a Ͼ2-fold increase in the final product concentration and in volumetric productivity. Thus far, we do not have a satisfying explanation for the stronger effect of pqo deletion on 2-ketoisovalerate production. It might be speculated that the transaminase B reaction is limiting in L-valine production, and therefore the effect of pqo deletion is less pronounced than in 2-ketoisovalerate production. However, the L-valine producer already overexpresses the transaminase B gene ilvE (6) , and thus this explanation seems unlikely.
The importance of the deletion of the transaminase B gene ilvE on 2-ketoisovalerate formation is corroborated by a recent study by Bartek et al. (3) . These authors analyzed the overexpression of L-valine biosynthesis genes in PDHC-deficient C. glutamicum strains in order to achieve an optimal L-valine production strain. With C. glutamicum ⌬aceE (pJC4ilvBNCD), the authors observed growth-decoupled production of L-valine and, in addition, the formation of 2-ketoisovalerate as a byproduct with a Y P/S of 0.58 mol per mol of glucose (3). This Y P/S is higher than that of C. glutamicum ⌬aceE ⌬ilvE (pJC4ilvBNCD) and comparable to that of our best 2-ketoisovalerate producer with deleted pqo (Fig. 4B) ; however, the L-valine producer showed a much lower substrate consumption (ca. 50%) and relatively low final titers of 2-ketoisovalerate (55 mM) and L-valine (22 mM). The same strain overexpressing ilvE (instead of ilvD) formed only 10 mM 2-ketoisovalerate (Y P/S of 0.052 mol per mol of glucose) and 104 mM L-valine (3) . In combination, these results indicate the importance of the transaminase B for L-valine formation and point to the contribution of the ilvE deletion to the production of 2-ketoisovalerate.
As previously found for L-valine production with PDHCdeficient C. glutamicum L-valine producers (6, 7), 2-ketoisovalerate production in medium containing initially glucose and acetate by the strains described here was decoupled from growth, i.e., took place only after depletion of acetate required for growth. The reason for the nonproducing phenotype of the L-valine producers during growth could recently be nailed down to a reduced glucose consumption rate in the presence of acetate (4) . A reduction of glucose utilization in the presence of acetate was first observed by Wendisch et al. (57) and is due to a repressive effect of the DeoR-type transcriptional regulator SugR on the expression of ptsG, ptsI, and ptsH (18, 20, 53) , encoding components of the phosphoenolpyruvate:sugar phosphotransferase system. In cells grown on glucose plus maltose, ptsG expression has been shown to be twice as high as in cells grown on glucose as sole carbon source, and this effect was independent of SugR (18) . In accordance with all of these findings, the L-valine nonproducing phenotype could be overcome by inactivating SugR, by replacing acetate by ethanol in the growth medium, or by the use of maltose as a cosubstrate in addition to glucose and acetate (4, 26) . As shown here, the 2-ketoisovalerate nonproducing phenotype of C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD) during growth could be also overcome by replacing acetate with ethanol; however, the final 2-ketoisovalerate titers were lower, and the overall production process was less efficient.
The fact that C. glutamicum ⌬aceE ⌬pqo ⌬ilvE (pJC4ilvBNCD) in fed-batch fermentations still excreted significant amounts of the by-products L-alanine and pyruvate into the medium suggests that 2-ketoisovalerate synthesis from pyruvate still represents a bottleneck for an improved 2-ketoisovalerate production process. One reason for the limitation might be that the strain also forms L-valine and the key enzyme of the 2-ketoisovalerate synthesis AHAS is feedback inhibited by this amino acid (50% inhibition at 0.9 mM [29] ). In favor of this hypothesis, Pospíšil et al. (39) found 2-ketoisovalerateforming mutants of Streptomyces cinnamonensis with an AHAS feedback resistant to L-valine during isolation and testing of UV-irradiated 2-ketobutyrate and L-valine-resistant mutants. A further reason for the limitation in 2-ketoisovalerate production might be an endproduct inhibition of one or more of the enzymes involved. In fact, we found ca. 50% inhibition of the AHAS enzyme by 100 mM 2-ketoisovalerate. Although the affinity of AHAS to this keto acid is much lower than that of L-valine, it is reasonable to speculate that this inhibition is VOL. 76, 2010 2-KETOISOVALERATE PRODUCTION WITH C. GLUTAMICUM 8059 on July 31, 2017 by guest http://aem.asm.org/ relevant in our 2-ketoisovalerate-producing strains and impedes a further improvement in production.
In spite of the different affinities of L-valine and 2-ketoisovalerate toward the C. glutamicum AHAS, we hypothesized a similar mechanism of feedback inhibition via the socalled regulatory IlvN subunit. However, examination of the kinetic parameters of AHAS in cell extracts revealed a different view. In contrast to the feedback inhibition of AHAS by L-valine (and the other BCAAs [14, 29] ), our results indicate a competitive inhibition of AHAS by 2-ketoisovalerate and thus an inhibition at the catalytic sites of AHAS in the IlvB subunits. This conclusion was further corroborated by analyzing the effects of 2-ketoisovalerate, 2-ketoisocaproate, and 2-keto-3-methylvalerate on the specific activity of AHAS ⌬C-T ilvN, which is a mutated enzyme shown to be insensitive toward BCAAs (5) . This AHAS showed the same inhibition pattern toward all 2-keto acids as the original WT AHAS, indicating also different inhibition mechanisms for L-valine and 2-ketoisovalerate inhibition.
Taken together, our results demonstrate that C. glutamicum ⌬aceE ⌬pqo ⌬ilvE with plasmid-bound overexpression of the L-valine biosynthetic genes ilvBNCD is a useful platform for overproduction of 2-ketoisovalerate and metabolites deriving from this 2-keto acid. However, the results also show that AHAS regulation is probably most important for the optimization of 2-ketoisovalerate production and thus represents a beneficial target for further strain development.
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